We've started IND-enabling studies on a small molecule corrector for Rho-associated autosomal dominant retinitis pigmentosa (Rho-adRP). I thought it would be fun to spend some time walking through our approach and why we are excited. Long 🧵1/

🚀 Excited to share our latest @biorxivpreprint by @CEStieger We unveil TRACERs - Transcriptional Regulation via Active Control of Epigenetic Reprogramming - a new small-molecule-based induced-proximity modality that silences transcription factors by recruiting endogenous

Thank you @alzforum for featuring our new preprint identifying regulators of disease states of microglia. Project led by @AmandaKMcQuade, computational analysis by @reetm09. Collaboration with the labs of @jamesknunez & Phil De Jager https://t.co/7EJJXOfgpU

Day 1 feedback. 😁 "Your team sequenced way quicker than I could analyze!!! Your team is amazing. I have been a fan of your company for quite a few years and this RNA-seq literally blew it out of the water. I am incredibly impressed by the quality of the data and obviously the

an absolute shame. @harvard cutting PhD admissions "The Organismic and Evolutionary Biology department will shrink its class size by roughly 75 percent to three new Ph.D. students [...] Molecular and Cellular Biology will reduce its figure to four new students, and Chemistry and

Come join @maya_m_arce @uchemedoh @zhou_jingtian and start your lab at @arcinstitute as a Science Fellow! Researchers receiving their PhD, MD, or MD/PhD between spring 2024 and summer 2026, are encouraged to apply. Applications are being reviewed starting January 12, 2026.

If @rookisaacman is being considered for NASA, I'm super excited. He dreamed up and executed the @inspiration4x mission bringing >$250M to @StJude and think would make an inspirational new leader for the next phase of @NASA!

This is an unfortunate position because while Amazon’s retail business shows signs of big tech monopoly that hurt the little guy, AWS is a story of how immense competition can drive down costs for the little guy. Nearly every company that was affected by that outage couldn’t

We’re building tools to support research in the life sciences, from early discovery through to commercialization. With Claude for Life Sciences, we’ve added connectors to scientific tools, Skills, and new partnerships to make Claude more useful for scientific work.

Damn. This is amazing. Loving this direct to consumer push.

+$45M on a $1.62B cap note from @EliLillyandCo, Duke, Section 32 and others -- just five months after our Series B. Lilly is flirting with becoming an Aging Company. Excited to have them back @newlimit and for more companies to go after the most important human ailment.

This article is a homecoming for me. As a PhD student, I focused on the growth-rate transcriptional regulation in yeast. Now, ~ 20 years later, we report protein regulation scaling with the growth rates of single cells in mammalian tissues. https://t.co/qwDYA3v55b

Second, the human diaspora has done these mutational scans with deep coverage. The problem is that we don't know what mutations do. With DMS, we can build those lookup maps, allowing us to collapse the rare variation onto the various functions of the gene and regress the function

Two big takeaways for me. First, I am super excited about using DMS as a drug discovery tool, on par with tools like structural biology. It provides a functional layer that sits on top of structure to understand things like cellular activity, mechanisms in cells, and how drugs

Another cool finding was that looking across variants in Tyk2 found through biobanks, we find that the protective effects seem to be mechanistically caused by reducing Tyk2 abundance... Likely because different immune pathways are differentially reliant on Tyk2 abundance, and

We also ran different compounds through various doses to pinpoint mutations that drive resistance and identify primary and secondary shell residues that mediate inhibition. At low doses, we can even find mutations that increase inhibition, thereby identifying regions we can build

By comparing the two DMSs, we can identify pockets that are important for signaling activity versus stability. This was key to identifying important orthosteric and allosteric sites vital for signaling, including the orthosteric and several allosteric sites in the pseudokinase,

This collab was relatively early in @OctantBio's history, and we learned a great deal about pushing the limits of quantitative DMS (Thanks to @bmsnews for taking a chance on us). We did a few DMSs, and published in this paper are full >23,000 variant DMSs looking at interferon

New preprint w/ @rplenge's group on the DMS of Tyk2. Led by @conor_j_howard & @diane_dickel @OctantBio. Insights across genetics, mechanism, allostery & SAR suggest a promising future for DMS as a central tool in drug discovery. Highlights in 🧵

NYC with old pals @harriswangnyc & @laserson

🤯🤯 A Paper from David Baker labs is here!!👇 Can we control immune cell behavior by precisely tuning how cytokine receptors are positioned in space relative to each other?@UWproteindesign @biorxivpreprint "Geometric Tuning of Cytokine Receptor Association Modulates Synthetic